



บริษัท ธนบุรี เมดิคอล เซ็นเตอร์ จำกัด(มหาชน)
Thonburi Medical Centre Public Company Limited

No. KDH.008/2024

August 9, 2024

Subject: Management Discussion and Analysis for Q2/2024
Attention: President of the Stock Exchange of Thailand
CC: The Securities and Exchange Commission

According to Thonburi Medical Centre Public Company Limited has submitted Financial Statements for Q2/2024 ended June 30, 2024 which were reviewed by the Independent Auditor and the Audit Committee. The company would like to report the operating results as follows:

Operating results for the three-month period ended June 30, 2024 (Q2/2024):-

In Q2/2024, net profit amounted to Baht 31.5 million, increasing Baht 4.5 million or 16.5 percent from the same period of previous year which had net profit Baht 27.0 million with mainly these followings:-

Revenue : Total revenue of Q2/2024 decreased from Q2/2023 with the amount Baht 62.4 million from

1. Increment from outpatient revenue, Bath 8.0 million or 7.3 percent which increased from Samitivej Allergy Institute, Samitivej Advance Eye and Lasik Center including Ear Nose Throat department. Inpatient revenue decreased Bath 70.9 million or 35.4 percent from Esthetic surgery according to a number of patients decreased and also changed business model.

Expenses : Total expenses decreased from Q2/2023 with the amount Bath 66.8 million from

1. Decreasing from cost of hospital operations Bath 26.6 million, 14.2% because of physicians and personnel fee declined in line with inpatient revenue down.
2. Decrement from administrative expenses Baht 40.2 million or 43.7% in resulting from referral fee decreased Baht 44.6 million according to a number of patients decreased and changed Esthetic surgery business model.

Please be informed accordingly.

Yours Sincerely,

.....
(Mr. Nivat Jeegungwal)

Authorized to sign on behalf of the company
Thonburi Medical Centre Public Company Limited